ArticlePloS one2013
Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.Human vaccines & immunotherapeutics · 2026Review
- Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024.NPJ vaccines · 2026Article
- Breast milk delivery of an engineered dimeric IgA protects neonates against rotavirus.Mucosal immunology · 2025Article
- Insights into recent advancements in human and animal rotavirus vaccines: Exploring new frontiers.Virologica Sinica · 2025Review
- Equine herpesvirus type 1 (EHV-1) replication at the upper respiratory entry site is inhibited by neutralizing EHV-1-specific IgG1 and IgG4/7 mucosal antibodies.Journal of virology · 2024Article
- Spectroscopic analysis of the bacterially expressed head domain of rotavirus VP6.Bioscience reports · 2024Article
- The Challenges and Opportunities of Next-Generation Rotavirus Vaccines: Summary of an Expert Meeting with Vaccine Developers.Viruses · 2022Article
- Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.Archives of virology · 2022Review
- The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.Viruses · 2022Review
- The dark side of the gut: Virome-host interactions in intestinal homeostasis and disease.The Journal of experimental medicine · 2021Review
- Protein transduction domain-mediated influenza NP subunit vaccine generates a potent immune response and protection against influenza virus in mice.Emerging microbes & infections · 2020Article
- Exploring rotavirus proteome to identify potential B- and T-cell epitope using computational immunoinformatics.Heliyon · 2020Article
- Intracellular neutralisation of rotavirus by VP6-specific IgG.PLoS pathogens · 2020Article
- Ehrlichia chaffeensis Outer Membrane Protein 1-Specific Human Antibody-Mediated Immunity Is Defined by Intracellular TRIM21-Dependent Innate Immune Activation and Extracellular Neutralization.Infection and immunity · 2019Article
- Article
- Neutralizing antibodies against porcine epidemic diarrhea virus block virus attachment and internalization.Virology journal · 2018Article
- Article
- Beyond binding: antibody effector functions in infectious diseases.Nature reviews. Immunology · 2018Review
- Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Characterization of a genetically heterogeneous porcine rotavirus C, and other viruses present in the fecal virome of a non-diarrheic Belgian piglet.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Several live attenuated rotavirus (RV) vaccines have been licensed, but the mechanisms of protective immunity are still poorly understood. The most frequent human B cell response is directed to the internal protein VP6 on the surface of double-layered particles, which is normally exposed only in the intracellular environment. Here, we show that the canonical VP6 antibodies secreted by humans bind to such particles and inhibit viral transcription. Polymeric IgA RV antibodies mediated an inhibitory effect against virus replication inside cells during IgA transcytosis. We defined the recognition site on VP6 as a quaternary epitope containing a high density of charged residues. RV human mAbs appear to bind to a negatively-charged patch on the surface of the Type I channel in the transcriptionally active particle, and they sterically block the channel. This unique mucosal mechanism of viral neutralization, which is not apparent from conventional immunoassays, may contribute significantly to human immunity to RV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.